Rituximab-Related Reversible Hepatocellular Damage

To the Editor, Since its approval in 1997 by the US Food and Drug Administration, use of rituximab (MabThera®, Roche,Switzerland) has become widespread, especially for the treatment of non-Hodgkin lymphoma (NHL) and chr...

Karbamazepine Bağlı Kırmızı Kan Hücresi Aplazisi: Bir Olgu Sunumu

3. Clinical Picture in Hematology

New in vitro effects of clopidogrel on platelets in hyperlipidemic and healthy subjects

Objective: We aimed to detect novel in vitro effects of clopidogrel on platelets by assessment of the following parameters: malondialdehyde, glutathione, nitrite, aggregation response, and expressions of P-selectin, fibr...

Prospective Evaluation of Non-Compliant Severe Hemophilia Patients

.